News & Updates

Obesity and metabolic comorbidities appear to be common among patients with large hepatocellular adenomas (HCAs) and adenomatosis, reports a study.

In children with newly diagnosed inflammatory bowel disease (IBD), overweight and obese status are not associated with worse disease activity at 1 year after diagnosis compared with normal weight, results of a study have shown.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are superior to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in reducing renal outcomes among patients with type 2 diabetes (T2D) in Hong Kong, a real-world population-based study by the University of Hong Kong has shown.

The neurokinin-3 receptor antagonist fezolinetant reduced the frequency and severity of menopause-associated vasomotor symptoms (VMS), according to results of the extension arm of the phase III Skylight 2 trial presented at ENDO 2022.

Bioavailability studies presented at ENDO 2022 showed that patients with hypothyroidism can safely take the liquid formulations of levothyroxine (LT4) 15 or 30 minutes before meals, without having to worry about food effect on bioavailability.

In euthyroid patients with nonalcoholic fatty liver disease (NAFLD), higher values of thyroid hormone sensitivity markers, such as the thyroid-stimulating hormone (TSH) index (TSHI) and thyroid feedback quantile-based index (TFQI), appear to aggravate the risk of advanced fibrosis, a recent study has found.

Parathyroidectomy yields excellent surgical outcomes in patients with primary hyperparathyroidism (PHPT), whether or not intraoperative localization technique (IOLT) or intraoperative parathyroid hormone (IOPTH) monitoring have been used, reports a recent study.